Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 520116168 series 3404634
Content provided by Aleksandra Zuraw, DVM, PhD, Aleksandra Zuraw, and DVM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Aleksandra Zuraw, DVM, PhD, Aleksandra Zuraw, and DVM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Why are billions of people still invisible in genomic research—and what does that mean for the future of precision medicine?
In this episode, I sit down with Victor Angel Mosti, founder and CEO of Omica.Ai, for one of the most insightful conversations I’ve recorded about data equity and building ethical, community-centered AI.
Victor shares not only his personal cancer story but also the staggering truth: Hispanic and Latino populations make up less than 1% of genomic datasets. This underrepresentation isn’t just a data gap—it’s a clinical risk.
We dive into disparities between healthcare systems, the promise of digital pathology as a low-cost entry point, the dangers of “parachute science,” and how Victor is building a living, ethical, transparent biobank through Omica. AI—built for true precision medicine rooted in community trust.
Highlights with Timestamps
- [00:00–01:40] Personal cancer experiences and diagnostic uncertainty
- [01:40–06:50] Victor’s medical journey across Mexico and the U.S.
- [06:50–11:42] The digitization gap: empathy vs. tech
- [11:42–16:43] The “coffee diversity” metaphor for genomic diversity
- [16:43–19:34] Funding disparities & the biotech cold-start problem
- [19:34–25:44] Digital pathology as a gateway to precision medicine
- [25:44–31:44] Avoiding “parachute science” and building community-first research
- [31:44–36:05] The Nagoya Protocol and benefit-sharing
- [36:05–41:47] Omica.Ai’s work, goals, and clinical-embedded approach
- [41:47–49:36] Creating future-proof, embedded biobanks
- [49:36–53:35] Blockchain for transparency and patient trust
- [53:35–54:39] Victor’s call to action: collaborate, include, and stay human
Resources from This Episode
- Omica.Ai – Community-driven precision medicine platform
- Nagoya Protocol – Framework for equitable biological use
Key Insights
- Cancer is personal—even for experts
- <1% representation of Latino genomes threatens clinical accuracy
- Digital pathology + AI can leapfrog infrastructure gaps
- Ethical biobanking requires trust, transparency, and local benefit
- Avoiding “parachute science” is essential
- Genetic diversity drives discovery—but only if we capture it
- Blockchain + dynamic consent = future of patient-centered data
174 episodes
))
